Ravindra Ganesh, MD, MBBS, FACP, Dip ABOM, Svetlana Blitshteyn, MD, FAAN, and Monica Verduzco-Gutierrez, MD, discuss Long COVID's prevalence—noting that 1 in 5 Americans and 1 in 10 patients post-COVID may be affected.
Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
18th Annual New York Lung Cancers Symposium®
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
View More
Illuminating the Power of Collaborative Care in nAMD and DME: Advancing the Shift to Treatment Innovations
February 2, 2025
Register Now!
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Pediatric-Inspired Asparaginase Regimens for Patients With Acute Lymphocytic Leukemia
View More
GU Tumor Board®: Real World Strategies to Inform Individualized Care in Renal Cell Carcinoma
View More
Health Equity is Essential to Overcoming Antimicrobial Resistance
February 6th 2025The antimicrobial resistance (AMR) crisis stems from natural microbial adaptation and the lack of new antimicrobials in development. Vulnerable populations worldwide, including within the US, are disproportionately affected, exacerbating the spread of resistance.
Levofloxacin Protects TB Contacts in Meta-Analysis but not RCTs
February 4th 2025Levofloxacin was associated with statistically significant reduction in tuberculosis developing in household contacts of persons with multidrug- resistant TB in a meta-analysis, but not in the constituent controlled trials.
Intravenous Antimicrobials: Is It Time to Push?
January 29th 2025Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.